Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Brown Capital Management International All Company Fund 2023 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Brown Capital Management International All Company Fund)

Primary Source Intelligence • Q3 2023 Letter Analysis

Brown Capital Management International All Company Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Brown Capital Management International All Company Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD+5.19%

Annualized+9.55%

Positioning StanceConstructive

GeographyGlobal

Digest Analysis

Quick Take

"Brown Capital's International All Company Fund focuses on exceptional growth companies across three strategic tranches."

Executive Summary

Brown Capital Management's International All Company Fund employs an Exceptional Growth Company approach across three portfolio tranches: holdings that overlap with their small company strategy, early-stage growth companies with revenue exceeding $500 million, and larger companies discovering new growth opportunities. The fund returned 5.19% in Q3 2024, underperforming the MSCI EAFE index by 214 basis points, primarily due to cyclical sector rotation following China's stimulus announcement. Key contributors included MercadoLibre, which reported 42% revenue growth and benefits from low Latin American e-commerce penetration, and MonotaRO, a Japanese MRO e-commerce platform capturing market share in a largely offline $70 billion market. Detractors included Novo Nordisk, despite strong GLP-1 obesity drug performance, due to supply challenges and pricing pressures, and Mobileye Global, which the team exited after concluding their thesis was wrong due to aggressive Chinese competition. The manager remains confident in their long-term fundamental approach while acknowledging short-term market volatility impacts.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The fund demonstrates high conviction through concentrated positions in named holdings with detailed thesis explanations for each. The manager provides specific position sizing context (REA market cap allowing sizable positions), discusses multi-year holding periods, and shows conviction by exiting Mobileye when thesis broke down. However, the absence of new position additions and the diversified nature across multiple themes prevents a higher score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager expresses cautious optimism about the reversal of global monetary policy from headwind to tailwind, noting central bank rate cuts and improved conditions for international equity investors. However, they acknowledge market volatility and the impact of cyclical rotations, showing measured rather than unambiguous bullishness.

Risk Appetite

10%

DefensiveAggressive

Defensive (10%)

The portfolio maintains its concentrated growth approach with no new additions in the quarter and one exit (Mobileye). The manager demonstrates selective risk appetite by exiting a position when thesis breaks down, but maintains conviction in existing holdings despite short-term underperformance.

Capital Deployment

43%

De-riskingDeploying

Net Neutral (43%)

The fund made no new additions during the quarter and exited one position (Mobileye Global). This represents net capital reduction rather than deployment, though the exit was thesis-driven rather than broad de-risking. No cash level data provided, but the activity pattern suggests slight de-risking.

Forward Guidance

15%

CautiousExpansionary

Cautious (15%)

The manager indicates no immediate deployment plans with zero additions in the quarter. They emphasize patience and long-term fundamental focus rather than active deployment, suggesting a monitoring stance rather than aggressive capital deployment.

Language Signal

20%

BearishBullish

Bearish (20%)

Language is balanced with both opportunity-focused terms (growth, market leadership, competitive advantages) and risk-aware language (challenges, headwinds, disappointing results). The tone is measured and analytical rather than directionally bullish or bearish.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The manager acknowledges several specific risks including supply challenges for pharmaceuticals, competitive pressures from Chinese companies, and market rotation impacts. However, these are discussed as manageable business risks rather than systemic threats, and the manager maintains confidence in long-term fundamentals.

Opportunity Density

35%

ScarceAbundant

Selective (35%)

The manager made no new additions in the quarter and focuses on existing holdings, suggesting limited new opportunities meeting their standards. They emphasize selectivity and patience, indicating a more constrained opportunity set rather than abundant attractive options.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

The manager demonstrates a multi-year investment horizon, holding Novo Nordisk since 2013 and MercadoLibre since 2013/2020. They explicitly state focus on long-term fundamentals over short-term market movements and describe patient capital approach. The 25-year strategy anniversary reinforces long-term orientation, though specific catalyst timelines prevent a higher score.